Abstract: TNG908 (Ralometostat) is a novel, brain-penetrant, small-molecule inhibitor of protein arginine methyltransferase 5 (PRMT5) designed to exploit the synthetic lethality associated with methylthioadenosine phosphorylase (MTAP) deletion in cancers. MTAP deletion, which frequently co-occurs with the loss of the tumor suppressor CDKN2A, is prevalent in 10-15% of all human cancers, including a significant proportion of glioblastomas (GBM). Unlike first-generation PRMT5 inhibitors that cause dose-limiting hematological toxicities due to a lack of tumor selectivity, TNG908 utilizes an MTA-cooperative mechanism to selectively bind and inhibit the PRMT5·MTA complex in MTAP-null cells. Extensive structure-activity relationship (SAR) optimization yielded a compound with high passive permeability and low efflux, enabling excellent blood-brain barrier penetration. Preclinical studies demonstrate that TNG908 drives robust, selective anti-tumor activity and extends survival in aggressive orthotopic glioblastoma models. Furthermore, TNG908 shows synergistic potential when combined with MAT2A or CDK4/6 inhibitors. This review synthesizes the discovery, pharmacological profile, molecular mechanism, and future therapeutic perspectives of TNG908 in the context of neuro-oncology.
1. Introduction
The advent of comprehensive cancer genome sequencing has illuminated critical genetic alterations that drive tumorigenesis, revealing novel therapeutic vulnerabilities. One of the most prevalent collateral vulnerabilities is the homozygous deletion of the methylthioadenosine phosphorylase (MTAP) gene, which occurs in 10-15% of all human cancers [1][2]. MTAP is located on chromosome 9p21 in close proximity to the well-known tumor suppressor gene CDKN2A, leading to frequent co-deletion. This genetic event is particularly prominent in central nervous system (CNS) malignancies, with approximately 40-44% of glioblastomas (GBM) harboring homozygous MTAP deletions [1][2].
MTAP is an essential enzyme in the methionine salvage pathway. Its loss results in the intracellular accumulation of its substrate, methylthioadenosine (MTA) [1]. Functional genomics screens have demonstrated that MTAP-deleted cancer cells exhibit a profound, selective dependence on the activity of protein arginine methyltransferase 5 (PRMT5), an enzyme responsible for symmetric dimethylation of arginine (SDMA) residues on proteins regulating RNA splicing, DNA damage response, and transcription [1][2]. Early clinical PRMT5 inhibitors were S-adenosylmethionine (SAM)-competitive or SAM-uncompetitive and inhibited PRMT5 irrespective of MTAP status. Consequently, these first-generation agents suffered from a narrow therapeutic index and dose-limiting hematological toxicities [1]. To overcome this, TNG908 was developed as a next-generation, MTA-cooperative PRMT5 inhibitor specifically designed to cross the blood-brain barrier (BBB) and selectively target MTAP-deleted tumors, including glioblastoma [1][2].
2. Pharmacological Activity
TNG908 exhibits potent and highly selective pharmacological activity against MTAP-deleted cancer cells. In vitro viability assays utilizing MTAP-isogenic cell lines demonstrated that TNG908 possesses a 15-fold selectivity for MTAP-null cells over MTAP-wild-type (WT) cells [1][2]. This selectivity translates robustly to in vivo models, where oral administration of TNG908 drove dose-dependent anti-tumor activity and durable tumor regressions across a wide panel of MTAP-deleted xenografts, including non-small cell lung cancer (NSCLC), colorectal cancer, and glioblastoma [1][2].
A defining pharmacological feature of TNG908 is its exceptional brain penetrance, making it highly relevant for neuro-oncology. The compound exhibits high passive permeability and is not a substrate for P-glycoprotein (P-gp) or Breast Cancer Resistance Protein (BCRP) efflux transporters [1]. In non-human primate (NHP) pharmacokinetic studies, which are highly predictive of human BBB penetration, TNG908 achieved a cerebrospinal fluid (CSF) to unbound plasma concentration ratio (Kp,uu,CSF) of 0.9, indicating ~60% free drug exposure in the CNS relative to plasma [1][2]. In a highly aggressive orthotopic U87MG MTAP-null glioblastoma xenograft model, TNG908 demonstrated 89% anti-tumor activity and significantly extended median overall survival by 53 days (a 3-fold increase) compared to vehicle controls [1].
3. Molecular Mechanism of Action
The molecular mechanism of TNG908 is rooted in the concept of synthetic lethality (or collateral lethality) driven by MTA accumulation. In normal cells, MTAP rapidly metabolizes MTA. However, in MTAP-deleted cancer cells, accumulated MTA binds to the PRMT5 enzyme complex, competing with the universal methyl donor SAM to form an inactive PRMT5·MTA complex [1].
TNG908 is designed to bind cooperatively with MTA to this specific complex. Biochemical and biophysical characterizations reveal that TNG908 acts as a reversible, tight-binding, substrate-competitive inhibitor. It binds to the PRMT5·MTA complex with an apparent inhibition constant (Ki,app) of 0.26 nM, representing a 12-fold increase in potency compared to its binding to apo-PRMT5 (Ki,app = 3.2 nM) [2]. By selectively targeting the PRMT5·MTA complex, TNG908 induces profound inhibition of PRMT5 activity—measured by the reduction of symmetric dimethylarginine (SDMA) marks—specifically in MTAP-null cells. This MTA-cooperative mechanism ensures that normal, MTAP-proficient cells are largely spared, thereby generating a wide therapeutic index [1][2].
4. Structure-Activity Relationship (SAR)
The discovery of TNG908 was driven by high-throughput screening (HTS) and structure-based drug design (SBDD). The initial hit was a low-molecular-weight compound featuring an oxamide core. X-ray crystallography revealed that the oxamide moiety forms critical hydrogen bonds with the PRMT5 active site (specifically with Ser578, Phe580, and Leu312), establishing it as a stable, non-electrophilic anchor for optimization [2].
SAR exploration focused on improving potency and BBB penetrance without inflating molecular weight or lipophilicity. A systematic "methyl walk" on the piperidine ring identified that a trans-5-methyl substitution significantly enhanced biochemical potency [2]. Concurrently, modifications to the pyridine ring were explored to exploit the MTA/SAM binding pocket. The introduction of a 6-amino group or a carboxamide on the pyridine ring established strong hydrogen bonds with the backbone carbonyl of Glu435 and the side chain of Glu444. This interaction sterically locked Glu435 into a rotamer that is incompatible with SAM binding, thereby reinforcing the MTA-cooperative selectivity [2].
To achieve optimal brain penetrance, the researchers needed to increase potency without adding traditional hydrogen-bond donors, which typically reduce permeability and increase efflux. Replacing a phenyl ring with a benzothiazole group proved to be the breakthrough. The benzothiazole engaged in a non-traditional C-S σ* orbital interaction with the carbonyl lone pair of Ser310. This unique substitution provided a substantial gain in potency while maintaining a low polar surface area (PSA), resulting in high permeability (MDCKII A-B = 16.4 cm/s) and low efflux (efflux ratio = 3), culminating in the clinical candidate TNG908 [2].
5. Current Limitations
Despite its robust preclinical profile, the development and application of TNG908 face certain limitations. First, while TNG908 drives tumor regressions in approximately 30% of MTAP-deleted xenograft models, there remain models where complete regressions are not achieved with single-agent therapy, indicating intrinsic or adaptive resistance mechanisms [1]. Functional genomics screens have identified that the upregulation of MAT2A (which synthesizes SAM) or WDR77 (which encodes MEP50, a PRMT5 co-factor) can reduce cellular sensitivity to MTA-cooperative PRMT5 inhibitors by altering the intracellular MTA/SAM ratio [1].
Additionally, there were theoretical concerns that MTAP-WT cells within the tumor microenvironment could metabolize free MTA, potentially depleting the MTA required for TNG908's cooperative mechanism. However, co-culture studies demonstrated that intracellular MTA levels in MTAP-null cells remain sufficient for TNG908 activity even in the presence of excess MTAP-WT cells [1]. Finally, from a clinical development standpoint, while TNG908 entered a Phase I/II clinical trial (NCT05275478) for patients with MTAP-deleted solid tumors including glioblastoma, new patient recruitment has been halted due to corporate portfolio prioritization [1].
6. Future Perspectives
The preclinical success of TNG908 highlights the vast potential of MTA-cooperative PRMT5 inhibitors in neuro-oncology. Because MTAP deletion is highly prevalent in glioblastoma and in cancers that frequently metastasize to the brain (such as melanoma and NSCLC), brain-penetrant agents like TNG908 represent a critical therapeutic avenue [1][2].
To overcome single-agent limitations, future perspectives heavily emphasize rational combination therapies. Preclinical data show that combining TNG908 with MAT2A inhibitors (e.g., AG-270) yields strong synergistic anti-tumor activity by further manipulating the MTA/SAM ratio in favor of PRMT5 inhibition [1]. Furthermore, because MTAP deletion is almost universally co-deleted with CDKN2A, MTAP-null tumors inherently lack p16INK4a, rendering them susceptible to CDK4/6 inhibition. Combining TNG908 with brain-penetrant CDK4/6 inhibitors, such as abemaciclib, has demonstrated significant combination benefits in both NSCLC and GBM models, regardless of the tumor's baseline sensitivity to single-agent CDK4/6 inhibition [1]. These combination strategies hold immense promise for maximizing the depth and durability of clinical responses in patients with MTAP-deleted brain malignancies.
